8-K: Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
8-K: Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
8-K：梯瓦公布2024年第三季度强劲的财务业绩，由仿制药业绩和创新投资组合增长带动；上调了2024年财务展望，包括收入、调整后的息税折旧摊销前利润和非公认会计准则每股收益
资讯热榜
更新时间